151342-35-7 Usage
Uses
Used in Cardiology:
RO-32-0432 is used as a PKC inhibitor for enhancing cardiac contractility and providing protection against heart failure. The inhibition of PKCα by RO-32-0432 has been associated with improved heart function and reduced risk of heart failure.
Used in Immunology:
RO-32-0432 is used as an immunomodulator for preventing T-cell activation and proliferation associated with chronic inflammatory responses in vivo. By inhibiting PKCα, it can help regulate the immune system and reduce inflammation, which may be beneficial in treating various autoimmune and inflammatory conditions.
Used in Pharmaceutical Research:
RO-32-0432 is used as a research tool for studying the role of PKC in various cellular processes and diseases. Its potent and selective inhibition of PKCα makes it a valuable compound for investigating the molecular mechanisms underlying various pathological conditions and for identifying potential therapeutic targets.
Biological Activity
Selective cell-permeable protein kinase C inhibitor. Displays slight selectivity for conventional PKC isoforms over Ca 2+ and atypical PKC isoforms; binding affinities for rat isoforms are 9, 28, 31, 37 and 108 nM for PKC's α , β Ι, β ΙΙ, γ and ε respectively. Orally available and prevents T-cell chronic inflammation in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 151342-35-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,1,3,4 and 2 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 151342-35:
(8*1)+(7*5)+(6*1)+(5*3)+(4*4)+(3*2)+(2*3)+(1*5)=97
97 % 10 = 7
So 151342-35-7 is a valid CAS Registry Number.
InChI:InChI=1/C28H28N4O2.ClH/c1-30(2)15-17-10-11-32-20(12-17)13-18-8-9-19(14-24(18)32)25-26(28(34)29-27(25)33)22-16-31(3)23-7-5-4-6-21(22)23;/h4-9,13-14,16-17H,10-12,15H2,1-3H3,(H,29,33,34);1H
151342-35-7Relevant articles and documents
Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction
Bit,Davis,Elliott,Harris,Hill,Keech,Kumar,Lawton,Maw,Nixon,Vesey,Wadsworth,Wilkinson
, p. 21 - 29 (2007/10/02)
The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competiti
